Literature DB >> 26786927

Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer.

Mark M Awad1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26786927     DOI： 10.1200/JCO.2015.64.2777

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  13 in total

1.  Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion.

Authors:  Félix Blanc-Durand; Raafat Alameddine; Anthony J Iafrate; Danh Tran-Thanh; Ying-Chun Lo; Normand Blais; Bertrand Routy; Mustapha Tehfé; Charles Leduc; Phillipe Romeo; Phillipe Stephenson; Marie Florescu
Journal:  Oncologist       Date:  2020-09-08

2.  Dramatic Response to Crizotinib in a Patient with Lung Cancer Positive for an HLA-DRB1-MET Gene Fusion.

Authors:  Kurtis D Davies; Terry L Ng; Adriana Estrada-Bernal; Anh T Le; Peter R Ennever; D Ross Camidge; Robert C Doebele; Dara L Aisner
Journal:  JCO Precis Oncol       Date:  2017-08-29

3.  MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.

Authors:  Xinyuan Lu; Nir Peled; John Greer; Wei Wu; Peter Choi; Alice H Berger; Sergio Wong; Kuang-Yu Jen; Youngho Seo; Byron Hann; Angela Brooks; Matthew Meyerson; Eric A Collisson
Journal:  Cancer Res       Date:  2017-05-18       Impact factor: 12.701

Review 4.  Effective implementation of novel MET pharmacodynamic assays in translational studies.

Authors:  Apurva K Srivastava; Tony Navas; William G Herrick; Melinda G Hollingshead; Donald P Bottaro; James H Doroshow; Ralph E Parchment
Journal:  Ann Transl Med       Date:  2017-01

Review 5.  Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer.

Authors:  Alia Daoud; Quincy S Chu
Journal:  Front Oncol       Date:  2017-09-29       Impact factor: 6.244

6.  Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors.

Authors:  Aino Paasinen-Sohns; Viktor H Koelzer; Angela Frank; Julian Schafroth; Aline Gisler; Melanie Sachs; Anne Graber; Sacha I Rothschild; Andreas Wicki; Gieri Cathomas; Kirsten D Mertz
Journal:  Neoplasia       Date:  2017-02-03       Impact factor: 5.715

7.  Simultaneous identification of clinically relevant single nucleotide variants, copy number alterations and gene fusions in solid tumors by targeted next-generation sequencing.

Authors:  Duarte Mendes Oliveira; Teresa Mirante; Chiara Mignogna; Marianna Scrima; Simona Migliozzi; Gaetano Rocco; Renato Franco; Francesco Corcione; Giuseppe Viglietto; Donatella Malanga; Antonia Rizzuto
Journal:  Oncotarget       Date:  2018-04-27

Review 8.  [Research Progress of Targeted Therapy for Anaplastic Lymphoma Kinase and Other Rare Driver Genes in Advanced Non-small Cell Lung Cancer].

Authors:  Quan Zhang; Shucai Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-01-20

9.  Antitumor Activity of DFX117 by Dual Inhibition of c-Met and PI3Kα in Non-Small Cell Lung Cancer.

Authors:  Yanhua Fan; Huaiwei Ding; Donghwa Kim; Duc-Hiep Bach; Ji-Young Hong; Yongnan Xu; Sang Kook Lee
Journal:  Cancers (Basel)       Date:  2019-05-05       Impact factor: 6.639

Review 10.  [MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].

Authors:  Limei Yin; You Lu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.